




RealRate

# PHARMACEUTICAL 2022

Sonnet BioTherapeutics Holdings Inc.  
Rank 290 of 466



RealRate

The First AI Rating Agency

[www.realrate.ai](http://www.realrate.ai)

The relative strengths and weaknesses of Sonnet BioTherapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet BioTherapeutics Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 42% points. The greatest weakness of Sonnet BioTherapeutics Holdings Inc. is the variable Net Income, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is 74%, being 3.5% points below the market average of 78%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 28,812               |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 6,703                |
| Liabilities, Non-Current                    | 31                   |
| Other Assets                                | 123                  |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 0                    |
| Other Liabilities                           | 0                    |
| Other Net Income                            | -22                  |
| Other Revenues                              | 609                  |
| Property and Equipment                      | 59                   |
| Research and Development                    | 16,635               |
| Selling, General and Administrative Expense | 8,937                |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 28,994               |
| Liabilities              | 6,734                |
| Expenses                 | 25,571               |
| Revenues                 | 609                  |
| Stockholders Equity      | 22,260               |
| Net Income               | -24,984              |
| Comprehensive Net Income | -24,984              |
| Economic Capital Ratio   | 74%                  |